Skip to main content
MDCX
NASDAQ Life Sciences

Medicus Pharma 的皮肤癌药物在阳性二期试验中实现 73% 的临床清除率

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$1.3
Mkt Cap
$35.259M
52W Low
$0.917
52W High
$8.94
Market data snapshot near publication time

summarizeSummary

Medicus Pharma 公布了其多柔比星微针阵列（D-MNA）(SKNJCT-003) 用于治疗基底细胞癌的阳性二期试验结果，结果显示 200µg 群体在第 57 天实现了 73% 的临床清除率和 40% 的组织学清除率。这些 "决策级" 结果是小型生物技术公司的重大去风险事件，验证了其科学假设并加强了其在二期试验结束（EOP2）与 FDA 会议前的地位。考虑到该公司最近的 1,530 万美元按市值发行和今年早些时候的 "持续经营" 警告，这一积极的发展尤其重要，因为强大的临床数据可以吸引合作伙伴并缓解资本担忧。投资者应该关注预计在 2026 年第二季度发布的最终临床研究报告（CSR）、EOP2 会议的结果以及任何潜在的战略合作伙伴关系或许可协议。

在该公告发布时，MDCX的交易价格为$1.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3525.9万。 52周交易区间为$0.92至$8.94。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed MDCX - Latest Insights

MDCX
Apr 24, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Medicus Pharma Faces Nasdaq Delisting, Discloses $11.5M Raised in Highly Dilutive ATM Program
Sentiment: Negative
View Wiseek Article
MDCX
Apr 23, 2026, 5:10 PM EDT
Filing Type: 424B3
Importance Score:
9
Medicus Pharma Expands At-The-Market Offering to $50M, Signaling Extreme Dilution Risk Amidst Financial Distress
Sentiment: Negative
View Wiseek Article
MDCX
Apr 21, 2026, 6:01 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Medicus Pharma Proposes Reverse Stock Split Up to 1:50 to Avoid Nasdaq Delisting
Sentiment: Negative
View Wiseek Article
MDCX
Apr 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Medicus Pharma Submits Optimized Phase 2 Protocol for Teverelix, Targeting $2B Market with Capital-Efficient Design
Sentiment: Positive
View Wiseek Article
MDCX
Mar 26, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Medicus Pharma's SkinJect Phase 2 Hits 80% ORR, Aims to Reduce Skin Cancer Surgeries
Sentiment: Positive
View Wiseek Article
MDCX
Mar 25, 2026, 4:49 PM EDT
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Discloses Going Concern Warning, Reports Heavy Dilution and Positive Phase 2 Data in Annual Filing
Sentiment: Negative
View Wiseek Article
MDCX
Mar 25, 2026, 4:30 PM EDT
Source: Access Newswire
Importance Score:
7
Medicus Pharma Reports Positive SkinJect Phase 2 Data, Secures $31.9M Capital
Sentiment: Positive
View Wiseek Article
MDCX
Mar 25, 2026, 4:08 PM EDT
Filing Type: 10-K
Importance Score:
9
Medicus Pharma Faces Critical Going Concern Warning Amidst Massive Dilution and Director's Large Selling Plan
Sentiment: Negative
View Wiseek Article
MDCX
Mar 06, 2026, 4:58 PM EST
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Secures $3.85M Through Equity Sales to Yorkville, Reducing Debt and Extending Runway
Sentiment: Neutral
View Wiseek Article
MDCX
Mar 06, 2026, 4:57 PM EST
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Secures $3.85M Through Equity Sales, Prepaying Debt
Sentiment: Neutral
View Wiseek Article